GPCR News

Post: Blog2_Post

GPCR News
- Mar 1, 2022
- 1 min read

ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships

Updated: Aug 23, 2022

March 2022

"February 17, 2022 08:00 AM Eastern Standard Time

SAN FRANCISCO & SHANGHAI- ShouTi Inc., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide range of chronic diseases, today introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi’s pipeline and pursuing drug discovery partnerships."

Recent Posts

See All

Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and...

August 2022 Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and Changes Name from ShouTi "San Francisco and Shanghai – August 1, 2022 – Structure Therapeutics

Jan Steyaert Named 2022 Jacob and Louise Gabbay Award Winner

Amgen to Acquire Chemocentryx for $4 Billion in Cash

August 2022 "THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally admin